期刊
MUSCLE & NERVE
卷 52, 期 4, 页码 521-526出版社
WILEY
DOI: 10.1002/mus.24621
关键词
clinical trials; DUX4; facioscapulohumeral muscular dystrophy; muscle pathology; pathology grade
资金
- National Institutes of Health [1PO1NS069539-01]
- Fields Center for FSHD and Neuromuscular Research
- University of Rochester CTSA of the National Center for Research Resources [UL1 RR024160]
- National Center for Advancing Translational Sciences of the National Institutes of Health
- Muscular Dystrophy Association
- CTSA grant from NCATS [KL2TR000119]
Introduction: As we move toward planning for clinical trials in facioscapulohumeral muscular dystrophy (FSHD), a better understanding of the clinical relationship with morphological changes in FSHD muscle biopsies will be important for stratifying patients and understanding post-therapeutic changes in muscle. Methods: We performed a prospective cross-sectional study of quadriceps muscle biopsies in 74 genetically confirmed FSHD participants (64 with FSHD type 1 and 10 with FSHD type 2). We compared a 12-point muscle pathology grade to genetic mutation, disease severity score, and quantitative myometry. Results: Pathology grade had moderate correlations with genetic mutation (rho = -0.45, P < 0.001), clinical severity score (rho = 0.53, P < 0.001), disease duration (rho = 0.31, P = 0.03), and quantitative myometry (rho = -0.47, P < 0.001). We found no difference in the frequency of inflammation between FSHD types 1 and 2. Conclusions: The pathology grade of quadriceps muscle may be a useful marker of disease activity in FSHD, and it may have a role in stratification for future clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据